The legal scrutiny follows a pair of unfavorable disclosures that rattled shareholders. On February 19, 2026, the company reported a revenue decline to $736.5 million for the full year, down from $792.1 million in 2024. More alarming to the market was the ballooning net cash usage, which jumped to $166.3 million from $77.9 million the previous year. Shares tumbled to $12.32 immediately following the report.

Investor sentiment soured further in April when the firm announced a 1-for-20 reverse stock split. Designed to regain compliance with NYSE listing standards and qualify for the Russell 3000, the maneuver failed to reassure the market. Trading on April 14, 2026, saw the stock shed another 22.51% to close at $8.40. Investors affected by these developments are now being urged to contact Danielle Peyton at Pomerantz LLP to discuss potential participation in class action litigation.